Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with companies executive. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Recently Added News

10/15/2021
AllergyBreakingCataractPharmaRegulation
US FDA Expands Labeling for Dextenza to Include Allergic Ocular Itching
US FDA Expands Labeling for Dextenza to Include Allergic Ocular Itching

Ocular Therapeutix announced Oct. 11 that the US FDA had approved its supplemental new drug application (sNDA) to add an indication for Dextenza for the treatment of ocular itching associated with ...

10/15/2021
BreakingDry EyePharmaRegulation
Allergan Agrees to $30 Million Settlement with Restasis End Payors
Allergan Agrees to $30 Million Settlement with Restasis End Payors

Allergan, now part of AbbVie, has agreed to a $30 million settlement to end part of a class action lawsuit involving end payors (such as insurers, pharmacy benefit managers, and pension funds) that...

10/15/2021
BreakingPharmaRegulationRetina
EMA Accepts Marketing Application for Lucentis Biosimilar from Xbrane, Stada
EMA Accepts Marketing Application for Lucentis Biosimilar from Xbrane, Stada

Sweden’s Xbrane Biopharma and its partner Stada, of Germany, announced Sept. 30 that the European Medicines Agency (EMA) had accepted the marketing authorization application (MAA) for their ranibiz...

10/15/2021
BreakingDealsIndiaSurgical
Dr. Agarwals Eye Hospitals Adds 100th Center as it Plans $133 Million Expansion in India
Dr. Agarwals Eye Hospitals Adds 100th Center as it Plans $133 Million Expansion in India

Dr. Agarwals Eye Hospitals will invest more than US $133 million over the next three years to increase its footprint across India to 200 hospitals and 500 outreach centers, India’s ETHealthWorld re...

10/15/2021
BreakingGene TherapyRegulationRetina
US FDA Clears IND for 4DMT’s Wet AMD Gene Therapy Candidate
US FDA Clears IND for 4DMT’s Wet AMD Gene Therapy Candidate

4D Molecular Therapeutics announced Oct. 6 that the US FDA had cleared the investigational new drug application (IND) for 4D-150 for wet age-related macular degeneration (wet AMD). 4D-150 is a dual...

10/15/2021
BreakingDealsGene TherapyRetina
Intellia, SparingVision to Collaborate on Ocular Therapies Using CRISPR/Cas9 Technology
Intellia, SparingVision to Collaborate on Ocular Therapies Using CRISPR/Cas9 Technology

Intellia Therapeutics, of Cambridge, Massachusetts, announced Oct. 13 a strategic collaboration with France’s SparingVision to develop ocular therapies utilizing CRISPR/Cas9 technology. Intellia wi...

10/15/2021
BreakingRefractiveSurgical
Zeiss’ SMILE Procedures Top 5 Million
Zeiss’ SMILE Procedures Top 5 Million

German company Zeiss announced Oct. 11 that ophthalmologists had performed more than 5 million SMILE procedures. Based on Zeiss’ previous announcements of SMILE milestones, surgeons appear to be pe...

10/15/2021
BreakingGene TherapyRegulationRetina
US FDA Grants Fast Track Status to GenSight’s Optogenetic Therapy Candidate for RP
US FDA Grants Fast Track Status to GenSight’s Optogenetic Therapy Candidate for RP

France-based GenSight Biologics announced Oct. 12 that the US FDA had granted Fast Track Designation to its candidate GS030, which combines AAV2-based gene therapy with optogenetics to treat retini...

10/15/2021
BreakingClinical TrialLow Vision
Pixium Shares Positive 3-Year Data for Prima Implant
Pixium Shares Positive 3-Year Data for Prima Implant

France’s Pixium Vision reported Oct. 13 positive long-term data from patients who received the Prima, its subretinal miniature photovoltaic wireless implant. The data were presented at The Eye and ...

10/15/2021
BreakingDiagnosticFundingRetina
Amydis Wins $3 Million NIH Grant to Explore Retinal Tracer for Parkinson’s
Amydis Wins $3 Million NIH Grant to Explore Retinal Tracer for Parkinson’s

Amydis, of San Diego, announced Oct. 11 that it had been awarded a $3 million grant to explore the presence of alpha synuclein (ASYN) in the retina of non-human primate models of Parkinson’s diseas...

10/15/2021
BreakingDealsDry EyePharma
Eurobio Scientific Receives $430 Thousand Milestone Payment from Allergan for Dry Eye Candidate
Eurobio Scientific Receives $430 Thousand Milestone Payment from Allergan for Dry Eye Candidate

Eurobio Scientific announced Oct. 6 that it had received from Allergan (now part of AbbVie) a milestone payment of $430 thousand to mark the submission of an investigational new drug (IND) applicat...

10/15/2021
BreakingCataractCorneaRefractive
Stephen D. McLeod, MD, to Lead the American Academy of Ophthalmology as CEO
Stephen D. McLeod, MD, to Lead the American Academy of Ophthalmology as CEO

The American Academy of Ophthalmology board of trustees announced Oct. 12 that it had unanimously selected Stephen D. McLeod, MD, 57, as the AAO’s next chief executive officer. McLeod chairs the de...

Past News Stories

10/15/2021
BreakingPharmaRetina
Isarna Names Claus Schalper, MBA, as CEO
Isarna Names Claus Schalper, MBA, as CEO

Germany-based Isarna Therapeutics reported Sept. 30 that it had appointed Claus Schalper, MBA, as chief executive officer. Isarna is developing a portfolio of antisense therapies targeting TGF-β si...

10/15/2021
BreakingCataractDry EyeRetina
Oculis Appoints Joanne R. Chang, MD, PhD, as Chief Medical Officer
Oculis Appoints Joanne R. Chang, MD, PhD, as Chief Medical Officer

Swiss drug developer Oculis announced Oct. 7 that it had appointed Joanne R. Chang, MD, PhD, as chief medical officer (CMO) and head of portfolio management. The company said Chang will be based in...

10/8/2021
BreakingRegulation
Francis Collins, MD, PhD, to Step Down as NIH Director with Legacy as ‘Extraordinary’ Scientist, YouTube Singing Star
Francis Collins, MD, PhD, to Step Down as NIH Director with Legacy as ‘Extraordinary’ Scientist, YouTube Singing Star

Francis Collins, MD, PhD, announced Oct. 5 that he would end his tenure as the director of the National Institutes of Health by the end of 2021. The physician-geneticist, 71, took office in August ...

10/8/2021
BreakingPharmaRegulationRetina
US FDA Accepts BLA for Coherus-Bioeq Ranibizumab Biosimilar Candidate
US FDA Accepts BLA for Coherus-Bioeq Ranibizumab Biosimilar Candidate

Coherus BioSciences announced Oct. 1 that the US FDA had accepted for review the 351(k) biologics license application (BLA) for CHS-201, a ranibizumab biosimilar candidate referencing Lucentis. The...

10/8/2021
BreakingDealsInstrumentsSurgical
Oertli Acquires Majority Interest in Ophthalmic Instrument Maker Domedics
Oertli Acquires Majority Interest in Ophthalmic Instrument Maker Domedics

Swiss company Oertli Instrumente reported Oct. 1 that it had acquired a majority interest in ophthalmic instrument maker Domedics AG, also of Switzerland. Terms of the deal were not disclosed. Oert...

10/8/2021
BreakingDeviceSurgical
Markus Weber, PhD, to Lead Carl Zeiss Meditec, as Ludwin Monz, PhD, Steps Down
Markus Weber, PhD, to Lead Carl Zeiss Meditec, as Ludwin Monz, PhD, Steps Down

Ludwin Monz, PhD, president and CEO of Carl Zeiss Meditec AG, has chosen not to accept another term in office, the German company announced Sept. 30. Markus Weber, PhD, will step into the role on J...

10/8/2021
BreakingDealsSurgical
BVI Invests in Beyeonics, Partners on Commercialization of Beyeonics One in US
BVI Invests in Beyeonics, Partners on Commercialization of Beyeonics One in US

Ophthalmic device maker BVI announced Oct. 4 that it would invest in Israel-based Beyeonics Vision and collaborate on the commercialization of the Beyeonics One surgical visualization system in the...

10/8/2021
BreakingCataractDealsSurgical
VSY and Alsanza to Operate Under Evmann Investments Holding BV
VSY and Alsanza to Operate Under Evmann Investments Holding BV

German companies VSY Biotechnology GmbH and Alsanza Medizintechnik und Pharma GmbH will operate under the umbrella of Evmann Investments Holding BV, of the Netherlands, Evmann announced Oct. 5. Evm...

10/8/2021
BreakingClinical TrialRetina
Gemini Cuts Workforce, Pipeline to Fund GA Candidate Through Pivotal Trials
Gemini Cuts Workforce, Pipeline to Fund GA Candidate Through Pivotal Trials

Gemini Therapeutics reported Oct. 5 that it would undergo a corporate restructuring to focus on its lead candidate’s pivotal trial in geographic atrophy (GA), an advanced form of dry age-related ma...

10/8/2021
BreakingFundingGene TherapyRetina
ATP Unveils Gene Therapy Startup Intergalactic Therapeutics
ATP Unveils Gene Therapy Startup Intergalactic Therapeutics

New York-headquartered ATP, a life sciences venture capital firm, announced Oct. 7 the debut of Intergalactic Therapeutics, a non-viral gene therapy platform funded with $75 million in Series A fin...

10/8/2021
BreakingClinical TrialDry EyePharma
Bausch + Lomb, Novaliq See Positive Results in Second Phase III Trial of NOV03 for Dry Eye with MGD
Bausch + Lomb, Novaliq See Positive Results in Second Phase III Trial of NOV03 for Dry Eye with MGD

Bausch + Lomb and Novaliq released on Sept. 30 statistically significant topline data from a second Phase III trial, MOJAVE, evaluating NOV03 (perfluorohexyloctane) eye drops in dry eye disease ass...

10/8/2021
BreakingClinical TrialGene TherapyRetina
Editas Reports Positive Data from Phase I/II Trial of CRISPR Technology for LHON
Editas Reports Positive Data from Phase I/II Trial of CRISPR Technology for LHON

Editas Medicine, of Cambridge, Massachusetts, reported Sept. 29 that its gene therapy candidate for Leber congenital amaurosis 10 (LCA10) yielded positive safety data at 15 months in the low- and m...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more